Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6-60
SponsorPeking University People's Hospital
About this trial
The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement. The main question it aims to answer is:
• Could be leukemia stem cell used for relapse prediction in acute myeloid leukemia patients with MLL-rearrangement? Leukemia stem cell will be detected at the same time for participants who detected minimal residual disease using bone marrow as part of their regular medical care to answer the question.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Patients who cannot recieve chemoterapy or allo-geneic hematopoietic stem cell transplantation.
Patients who cannot comply with the study.
Trial population
Acute myeloiud leukemia patients with MLL arrangement aging 6-60 years recieving chemoterapy or allo-geneic hematopoietic stem cell transplantation will be enrolled.
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
Detection of leukemia stem cell using multiparameter flow cytometry
Diagnostic testFor AML patients with MLL rearrangement enrolled, leukemia stem cell will be detcted at diagnosis and during follow-up. A traditional Minimal residual disease was deteced as normal medical care, simultaneously, leukemia stem cell will be detcted using the sample bone marrow sample.
Treatment groups
210 Participants
are divided into 1 treatment groupGroup A: AML patients with MLL rearrangement1 intervention
Trial outcomes
Primary outcomes
1
Relapse
Relapse was defined by the morphological evidence of disease in the peripheral blood, BM or extramedullary sites
Time frame
Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.Secondary outcomes
1
leukemia-free survival
Leukemia-free survival was defined as survival in continuous complete remission.
Time frame
Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.2
overall survival
Overall survival referred to patients who survived until the final follow-up time point
Time frame
Immediately after chemotheray or allo-SCT, through study completion, median follow-up on an average of 1 year.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov